Physician profile
Jon M Stevens
NPI 1780758367
$4,347.78
in general payments reported to CMS, 2019-2025
36 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,027 · 2022: $757 · 2023: $340 · 2024: $520 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $574.88 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $471.03 | 2021-2025 | |
| Amgen INC. | $432.40 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.25 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $314.79 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $245.35 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $232.51 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.48 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $167.60 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $157.59 | 2021-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $126.88 | 2024-2025 | Assure Wcd |
| Chiesi USA, INC. | $119.68 | 2021-2025 | Cleviprex, Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $97.55 | 2023-2025 | |
| Lilly USA, LLC | $78.73 | 2023-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $68.45 | 2021-2024 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.27 | 2021-2022 | |
| Boston Scientific Corporation | $61.84 | 2021-2023 | Watchman Access System |
| Edwards Lifesciences Corporation | $57.85 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $52.97 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $51.25 | 2021-2023 | |
| Tactile Systems Technology INC | $49.62 | 2021-2025 | Flexitouch Plus, Nimbl |
| Alnylam Pharmaceuticals INC. | $49.14 | 2022-2025 | Amvuttra |
| Itamar Medical INC | $43.18 | 2021-2022 | |
| Esperion Therapeutics, INC. | $42.08 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $26.22 | 2022 | |
| Liquidia Technologies, INC. | $24.67 | 2025 | Yutrepia |
| Shield Therapeutics INC | $24.51 | 2023 | Accrufer |
| Kiniksa Pharmaceuticals, LTD. | $19.34 | 2021 | |
| Lucid Diagnostics INC. | $17.98 | 2023 | |
| Altathera Pharmaceuticals LLC | $17.22 | 2025 | Sotalol Hydrochloride |
| Kowa Pharmaceuticals America, INC. | $16.70 | 2021 | |
| Bridgebio Pharma, INC. | $16.49 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $15.57 | 2021 | |
| Daiichi Sankyo INC. | $14.33 | 2025 | Injectafer |
| Acacia Pharma INC | $14.22 | 2021 | |
| Glaxosmithkline, LLC. | $14.16 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.